Other approaches include combining anti-PD1 therapy with something which generates cytotoxic cell death (such as chemotherapy or radiation) or combining anti-PD1 therapy with targeted therapies that remodel the tumor microenvironment such as PI3K inhibitors, mTOR inhibitors, cyclin-dependent kinase inhibitors. This evidence concerns the gene MTOR and neoplasm.